In a market dominated by mega-cap tech stocks and large-scale restaurant conglomerates, it’s easy to overlook smaller, emerging companies quietly carving out growth niches. One such company is BT Brands, Inc. (NASDAQ: BTBD), a micro-cap fast-casual dining operator based in North Dakota.

Carisma Therapeutics, Inc. (NASDAQ: CARM) is quickly emerging as a transformative player in the cell therapy landscape. While many investors are familiar with T-cell based therapies like CAR-T, Carisma has taken a differentiated approach by engineering macrophages — the innate immune system’s frontline defenders — to directly attack tumors and reshape the tumor microenvironment.

SHANGHAI, August 28, 2025 — Gamehaus Holdings Inc. (“Gamehaus” or the “Company”), a technology-driven mobile game publisher listed on Nasdaq under the ticker GMHS, is capturing investor attention with two pivotal developments: the authorization of a US$5 million share repurchase program and the release of its interim financial results for the first nine months of fiscal 2025.

Ask any seasoned investor what makes a technology business truly valuable, and you’ll often hear one word: recurring. Unlike one-off sales that constantly require new customers, recurring revenue compounds over time, delivering predictability and operating leverage. It’s why subscription businesses, SaaS platforms, and ad-driven ecosystems often trade at premium valuations

FDA Fast Track Momentum: On August 26, 2025, Allarity Therapeutics saw its stock skyrocket—up nearly 100%, with some sources even reporting over 110%—after the U.S. FDA granted Fast Track designation to stenoparib, its investigational treatment for advanced ovarian cancer Investing.com+12TipRanks+12Allarity Therapeutics+12.